U.S. markets close in 3 hours 28 minutes

FibroGen, Inc. (FGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
50.01+0.15 (+0.30%)
As of 12:32PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close49.86
Open50.34
Bid50.16 x 1300
Ask50.27 x 800
Day's Range48.78 - 50.56
52 Week Range22.65 - 57.21
Volume215,519
Avg. Volume713,300
Market Cap4.551B
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-2.57
Earnings DateMar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est62.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
    GlobeNewswire

    FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

    SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. Dial-In InformationLive (U.S./Canada): (877) 658-9081Live (International): (602) 563-8732Confirmation number: 3055327 A replay of the webcast and investor presentation will be available shortly after the call for a period of 30 days. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and use passcode 3055327. About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). For more information, please visit www.fibrogen.com. Contacts:FibroGen, Inc. Investors:Michael Tung, M.D.Corporate Strategy / Investor Relations 1.415.978.1434mtung@fibrogen.com Media:Jennifer Harrington +1.610.574.9196Jennifer.Harrington@gcihealth.com

  • FibroGen to Present at Upcoming Investor Conferences
    GlobeNewswire

    FibroGen to Present at Upcoming Investor Conferences

    SAN FRANCISCO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences: 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 at 3:40 PM Eastern TimeCowen 41st Annual Health Care Conference on March 2, 2021 at 12:50 PM Eastern Time A live audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days. About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). For more information, please visit www.fibrogen.com. Contact:FibroGen, Inc. Investors:Michael Tung, M.D.Corporate Strategy / Investor Relations1.415.978.1434mtung@fibrogen.com Media:Jennifer Harrington +1.610.574.9196Jennifer.Harrington@gcihealth.com